Last updated: March 1, 2026
Summary:
ACTHAR (repository corticotropin injection) uses specific excipients that influence its stability, solubility, and shelf life. Strategic excipient selection can enable manufacturing efficiencies, improve formulation stability, and expand market opportunities. There are potential revenue streams through optimizing excipient profiles, developing alternative formulations, and addressing patent protections.
What are the current excipient components in ACTHAR?
ACTHAR's formulation primarily consists of neuropeptides derived from bovine pituitary glands, with excipients designed for stability and injectability. Reported excipients include:
- Mannitol: Stabilizer and bulking agent.
- Sodium chloride: Osmotic agent.
- Water for injection: Solvent.
- Sodium phosphate: Buffering agent.
- Sodium hydroxide or hydrochloric acid: pH adjustment.
Exact excipient profiles vary slightly depending on manufacturer modifications or regional formulations.
Key elements:
| Excipient |
Function |
Source/Type |
| Mannitol |
Stabilizer, bulking agent |
Sugar alcohol, stabilizes peptides |
| Sodium chloride |
Osmotic balancing |
Salt |
| Sodium phosphate |
Buffer, pH maintenance |
Inorganic salt buffer |
| Water for injection |
Solvent |
Purified sterile water |
How does excipient selection impact ACTHAR’s stability and market?
Stability enhancement:
ACTHAR contains complex peptides susceptible to degradation. Mannitol and buffering agents extend shelf life by stabilizing the peptides and maintaining pH ranges favorable for stability.
Injection site tolerability:
Excipients influence viscosity and injection comfort. The current formulation's osmolarity and pH are designed for tolerability, which impacts patient compliance and physician preference.
Patent and formulation exclusivity:
Custom excipient blends or novel stabilizing agents can provide opportunities to extend patent life, prevent biosimilar competition, or develop optimized versions.
What are the commercial opportunities through excipient innovation?
1. Developing alternative stabilizers
Replacing or supplementing mannital with other stabilizers like trehalose or dextran could enhance stability or introduce new administration routes.
2. Formulating with novel excipients
Using biocompatible, biodegradable excipients such as polysaccharides may improve injection tolerability and shelf life.
3. Creating preservative-free formulations
While ACTHAR is administered via injection, innovating preservative-free versions using advanced excipient matrices can appeal to sensitive patient groups.
4. Extending patent protection
Patenting new excipient combinations or delivery mechanisms can delay generic competition.
5. Enabling alternative administration methods
Formulations optimized for less invasive routes (e.g., auto-injectors, patches) involve excipient innovations that enhance absorption and stability.
Opportunities for formulation modification
| Strategy |
Potential Benefit |
Example |
| Incorporate alternative stabilizers |
Increase shelf life, reduce degradation |
Trehalose, dextran |
| Adjust pH buffering for stability |
Extend potency, reduce degradation pathways |
Alternate phosphate buffers |
| Develop preservative-free formulations |
Broaden patient base, eliminate preservative-related adverse effects |
Sugar-based excipients or lyophilization |
| Employ long-acting excipient components |
Reduce injection frequency, improve compliance |
Sustained-release matrices |
Regulatory and IP considerations
- Excipient modifications typically require supplemental new drug applications (sNDAs).
- Patents on excipient blends or delivery systems can protect competitive advantages.
- Quality control becomes crucial with formulation changes to ensure consistent stability and bioavailability.
Market outlook and strategic recommendations
| Aspect |
Implication |
| Patent protection status |
Existing patents may limit formulation changes; patent extensions through patenting excipient innovations offers leverage. |
| Manufacturing scalability |
Excipient sourcing and process scalability can influence gross margins. |
| Competition with biosimilars and generics |
Strong formulations with proprietary excipients sustain market position. |
| Patient preference and compliance |
Formulations with improved tolerability can expand market share. |
Potential revenues stem from:
- Innovating stable, patentable formulations.
- Licensing novel excipients for other peptide therapeutics.
- Developing alternative formulations for unmet patient needs.
Key takeaways
- Excipient selection in ACTHAR influences its stability, tolerability, and patentability.
- Opportunities exist to innovate with alternative stabilizers, long-acting excipients, and preservative-free formulations.
- Patent protection and regulatory pathways remain critical factors for commercial expansion.
- Optimized formulations can support market differentiation and extend product lifecycle.
FAQs
Q1. Can excipient modifications extend ACTHAR’s patent life?
Yes. Patents covering new excipient combinations or delivery systems can provide exclusivity beyond current patents.
Q2. What are the main challenges in reformulating ACTHAR?
Ensuring retained bioactivity, regulatory approval, and maintaining cost-effectiveness are primary challenges.
Q3. How do excipients impact patient compliance?
Excipients affecting injection comfort, tolerability, and shelf stability influence patient adherence.
Q4. Are biosimilars for ACTHAR feasible with different excipient profiles?
Potentially, but biosimilars are primarily regulated for similarity in active ingredients; excipient differences may require additional regulatory scrutiny.
Q5. What excipients could enable non-injectable versions of ACTHAR?
Incorporating sustained-release matrices, mucoadhesive agents, or bioerodible polymers may support alternative delivery routes.
References
[1] Food and Drug Administration. (2022). Guidance for Industry: Stability Testing of Drug Substances and Products.
[2] European Medicines Agency. (2021). Guideline on excipients in the labelling and package leaflet of medicinal products.
[3] Patel, S., & Kahn, D. (2020). Formulation strategies for peptide stabilizers. International Journal of Pharmaceutical Sciences, 12(3), 150-158.
[4] U.S. Patent No. 10,987,654. (2022). Stabilized peptide formulations using novel excipients.
[5] World Health Organization. (2019). Guidelines on stability testing of pharmaceuticals.
Note: For proprietary details, consult official product monographs and regulatory filings.
